Navigation Links
Bionovo Reports Third Quarter 2008 Financial Results
Date:11/3/2008

arly signs of clinical efficacy. The Phase 2 part of

the trial is now open for enrollment at 17 clinical sites in the

U.S., and is expected to enroll 80 patients in the trial. There are

currently over 160,000 women living with metastatic breast cancer in

the U.S.

-- The Company presented an analysis of the metabolism of one of the

active chemical ingredients of MF101, the Company's drug candidate

for the treatment of menopausal hot flashes. The presentation, to

the American Society for Pharmacology and Experimental Therapeutics,

Drug Metabolism and Disposition, adds to the growing body of data

supporting MF101's mechanism of action, safety and potential

potency, as well as furthering the intellectual property protection

for the Company.

-- Also on MF101, the Company released data from its previous Phase 2

study that showed MF101's superior efficacy with respect to "night

sweats" or "night awakenings due to hot flashes" -- a particularly

debilitating form of hot flash for which many women seek medical

treatment and improved quality of life. This adds to the increasing

evidence of the possible efficacy of MF101 and the market

opportunity awaiting MF101 if and when it is approved by the FDA and

put on the market.

-- The Company is currently in discussions with the FDA on the specific

requirements for progression to Phase 3 pivotal trials of MF101. The

Company expects to have resolution, and to be in a position to

continue the clinical development and trials for MF101, by the end

of the year.

-- The Company presented a report to the North American Menopause

Society (NAMS), showing laboratory results of superior efficacy for

VG101, the Company's drug candidate for menopausal vagin
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... (Q2 2015: +14% CER / 20% of sales) led the regional ... China , as well as solid contributions from Korea, India ... / Middle East / Africa ... Germany , Turkey and the United ... grew 11%, excluding U.S. HPV sales, on demand across all customer classes. The ...
(Date:7/29/2015)... July 29, 2015  AsureQuality and Ubiquitome have ... for applications in food and primary production sectors. ... real-time PCR device, the Freedom4. AsureQuality ... to the supermarket shelf for producers, processors and ... in animal disease control and pest management and ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... its GHS Label Guide . To align chemical container labeling with OSHA’s ... includes explanations of label components, an example of an accurate label, and pictogram ...
(Date:7/29/2015)... 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) announced ... be released on Thursday, August 13, 2015, before the ... management will host a conference call to discuss the ... release outlining the financial results and business update will ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference ...
Breaking Biology Technology:QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Brady Announces a New GHS Label Guide 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
... , BIRMINGHAM, Ala. , Jan. 19 ... it comes to cholesterol. According to a new study, a lipoprotein ... can be labeled "bad cholesterol." The landmark study Genetic Variants ... in the New England Journal Of Medicine provides the ...
... BANGALORE, India , January 19 , ... Excellence , A team of cardiac experts led by ... Network Hospital of Fortis),has performed a major open heart surgery on a 2-year-old ... defect called - Tetralogy of,Fallot or complex blue baby syndrome. , ...
... , , RANCHO SANTA MARGARITA, Calif. , Jan. ... important for the development, growth, and maintenance of a healthy body, ... D within minutes of whole body exposure to sunlight. From what ... by chance," states Dr. John Cannell , Executive Director, Vitamin ...
Cached Biology Technology:New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 2New Study: Lp(a) Joins LDL as Heart Disease Risk Factor 32-Year-old Baby With Complex Heart Deformity Undergoes Major Open Heart Surgery at Wockhardt Hospitals, Bangalore - (now a Network Hospital of Fortis) Without any Blood Transfusion 22-Year-old Baby With Complex Heart Deformity Undergoes Major Open Heart Surgery at Wockhardt Hospitals, Bangalore - (now a Network Hospital of Fortis) Without any Blood Transfusion 3Cancer, Heart Disease, Stroke, Diabetes, Chronic Pain and Depression Share a Major Pathology Factor 2Cancer, Heart Disease, Stroke, Diabetes, Chronic Pain and Depression Share a Major Pathology Factor 3
(Date:7/8/2015)... SPRINGS, Florida , July 8, 2015 ... constantly evolving as this summer,s must have products such as ... in demand as popularity for biometrics based devices continues to ... are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... has announced the addition of the "Natural ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image ... to their offering. The key vendors ... Google, HP, IBM Corporation, Microsoft Corporation, NetBase Solutions, ...
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... dinosaurs, and he or she will likely tell you that ... to prominence and you,ll likely get a blank stare. Even ... But now, as EARTH explores in a feature in the ... the rise of dinosaurs. Learn more about this eye-opening ...
... Researchers at the University of North Carolina at Chapel Hill ... to programmed cell death or apoptosis. This molecule, a ... been shown to be in short supply in certain neurodegenerative ... discovery could herald a new treatment to prompt brain cells ...
... unable to distinguish colors, even though their close relatives ... new research by Dr. Nathan Scott Hart and colleagues ... of Queensland in Australia. Their study shows that although ... of light levels, they only have a single long-wavelength-sensitive ...
Cached Biology News:New molecule could save brain cells from neurodegeneration, stroke 2New molecule could save brain cells from neurodegeneration, stroke 3Are sharks color blind? 2
... provide two highly efficient methods of identifying ... preparation. By using the large-scale screen method ... do is to transfer partial colonies of ... plates into the solutions provided by the ...
GLP-1 (HYB 147-12)...
... Immunogen KLH-conjugated, synthetic ... 54-75 (RRGPHRNPG-PGDDDGQRSRSSS) of mouse p19ARF. ... to amino acids 62-75. Clone ... Routinely evaluated by immunoblot. ...
EDTA, tetrasodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99-101% (as is).Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemicals, Ul...
Biology Products: